|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Investigation |
1 Reproductive Biology and Adult Endocrinology Program, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland; 2 Nuclear Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland; 3 Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Maryland; and 4 Department of Medicine, Faculty of Medicine, P.J.
afárik University, Ko
ice, Slovak Republic
Correspondence: For correspondence or reprints contact: Karel Pacak, Section on Medical Neuroendocrinology, Reproductive Biology and Adult Endocrinology Program, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, CRC, 1 East, Room 1-3140, 10 Center Dr., MSC-1109, Bethesda, MD 20892-1109. E-mail: karel{at}mail.nih.gov
We compared functional imaging modalities including PET with 6-18F-fluorodopamine (18F-DA) with 123I-metaiodobenzylguanidine (123I-MIBG) and somatostatin receptor scintigraphy (SRS) with 111In-pentetreotide in nonmetastatic and metastatic pheochromocytoma (PHEO). Methods: We studied 25 men and 28 women (mean age ± SD, 44.2 ± 14.2 y) with biochemically proven nonmetastatic (n = 17) or metastatic (n = 36) PHEO. Evaluation included anatomic imaging with CT or MRI and functional imaging that included at least 2 nuclear medicine modalities: 18F-DA PET, 123I-MIBG scintigraphy, or SRS. Sensitivity of functional imaging versus anatomic imaging was assessed on a per-patient and a per-region basis. Results: For this available cohort, on a per-patient basis overall sensitivity (combined for nonmetastatic and metastatic PHEO) was 90.2% for 18F-DA PET, 76.0% for 123I-MIBG scintigraphy, and 22.0% for SRS. On a per-region basis, overall sensitivity was 75.4% for 18F-DA PET, 63.4% for 123I-MIBG scintigraphy, and 64.0% for SRS. Conclusion: If available, 18F-DA PET should be used in the evaluation of PHEO, because it is more sensitive than 123I-MIBG scintigraphy or SRS. If 18F-DA PET is not available, 123I-MIBG scintigraphy (for nonmetastatic or adrenal PHEO) and SRS (for metastatic PHEO) should be the first alternative imaging methods to be used.
Key Words: radionuclide imaging 18F-fluorodopamine 123I-metaiodobenzylguanidine 111In-pentetreotide pheochromocytoma
COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
![]() |
F. Imani, V. G. Agopian, M. S. Auerbach, M. A. Walter, F. Imani, M. R. Benz, R. A. Dumont, C. K. Lai, J. G. Czernin, and M. W. Yeh 18F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas J. Nucl. Med., April 1, 2009; 50(4): 513 - 519. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |